Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB1 | P15086 | 2/20 | 0.52 |
| ▸ | CASP3 | P42574 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
| ▸ | CTSB | P07858 | 3/20 | 0.48 |
| ▸ | CTSK | P43235 | 3/20 | 0.48 |
| ▸ | CTSS | P25774 | 2/20 | 0.48 |
| ▸ | TACR1 | P25103 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20749075 | 0.85 | CPB1 (0.58) | CPB1CASP3ALDH1A1GAATSHR | |
| SCHEMBL28914414 | 0.85 | CPB1 (0.58) | CPB1CASP3ALDH1A1GAATSHR | |
| SCHEMBL28914412 | 0.85 | CPB1 (0.58) | CPB1CASP3ALDH1A1GAATSHR | |
| SCHEMBL19630135 | 0.85 | CPB1 (0.58) | CPB1CASP3ALDH1A1GAATSHR | |
| SCHEMBL6612597 | 0.82 | EPHX1 (0.63) | CPB1CASP3ALDH1A1GAATSHR | |
| SCHEMBL30482174 | 0.81 | CASP3 (0.53) | CPB1CASP3ALDH1A1GAATSHR | |
| SCHEMBL19086685 | 0.81 | CASP3 (0.53) | CPB1CASP3ALDH1A1GAATSHR | |
| SCHEMBL30963623 | 0.81 | CASP3 (0.53) | CPB1CASP3ALDH1A1GAATSHR | |
| SCHEMBL2848373 | 0.81 | ALDH1A1 (0.58) | CPB1CASP3ALDH1A1GAATSHR | |
| SCHEMBL8322874 | 0.81 | CPB1 (0.51) | CPB1CASP3ALDH1A1GAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216803-A1 | ORNITHINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-08-26 | — | — | US | disclosed |
| EP-2141147-A1 | ORNITHINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2010-01-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216803-A1 | ORNITHINE DERIVATIVE | PTGER4, OXER1, ODC1 | CPB1 1940/4885CASP3 3838/4885ALDH1A1 1007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.